TY - JOUR
T1 - The development of quality indicators for systemic lupus erythematosus using electronic health data
T2 - A modified RAND appropriateness method
AU - Yajima, Nobuyuki
AU - Tsujimoto, Yasushi
AU - Fukuma, Shingo
AU - Sada, Ken ei
AU - Shimizu, Sayaka
AU - Niihata, Kakuya
AU - Takahashi, Ryo
AU - Asano, Yoshihide
AU - Azuma, Teruhisa
AU - Kameda, Hideto
AU - Kuwana, Masataka
AU - Kohsaka, Hitoshi
AU - Sugiura-Ogasawara, Mayumi
AU - Suzuki, Katsuya
AU - Takeuchi, Tsutomu
AU - Tanaka, Yoshiya
AU - Tamura, Naoto
AU - Matsui, Toshihiro
AU - Mimori, Tsuneyo
AU - Fukuhara, Shunichi
AU - Atsumi, Tatsuya
N1 - Funding Information:
This study was supported by JSPS KAKENHI Grant Number 16H05267. We are grateful to Nobuo Kuramoto (Kyoto University) for the consultations during the QI item selection. We would also like to thank Yuki Kataoka (Hyogo Prefectural Amagasaki General Medical Center) and Mikako Goto (National Center for Child Health and Development) for assistance with the literature searches.
Publisher Copyright:
© 2019, © 2019 Japan College of Rheumatology.
PY - 2020/5/3
Y1 - 2020/5/3
N2 - Objective: Quality indicators (QIs) are tools that standardize evaluations in terms of the minimum acceptable quality of care, presumably contributing for the better management of patients with systemic lupus erythematosus (SLE). This study aimed to develop QIs for SLE using electronic health data. Methods: The modified RAND/UCLA Appropriateness Method was used to develop the QIs. First, a literature review was conducted. Second, the candidate QI items that were available to be evaluated using the electronic health data were extracted. Third, the appropriateness of the items was assessed via rating rounds and panelists’ discussions. Results: We found 3621 articles in the initial search. Finally, 34 studies were reviewed, from which 17 potential indicators were extracted as candidate QIs. Twelve indicators were selected as the final QI set through the process of appropriateness. The median appropriateness of these 12 indicators was at least 7.5, and all of them were without disagreement. The QI included assessment of disease activity, treatment of SLE, drug toxicity monitoring, treatment of glucocorticoid complications, and assessment of SLE complications. Conclusion: We formulated 12 QIs for the assessment of patients with SLE based on electronic medical data. Our QI set would be a practical tool as a quality measure.
AB - Objective: Quality indicators (QIs) are tools that standardize evaluations in terms of the minimum acceptable quality of care, presumably contributing for the better management of patients with systemic lupus erythematosus (SLE). This study aimed to develop QIs for SLE using electronic health data. Methods: The modified RAND/UCLA Appropriateness Method was used to develop the QIs. First, a literature review was conducted. Second, the candidate QI items that were available to be evaluated using the electronic health data were extracted. Third, the appropriateness of the items was assessed via rating rounds and panelists’ discussions. Results: We found 3621 articles in the initial search. Finally, 34 studies were reviewed, from which 17 potential indicators were extracted as candidate QIs. Twelve indicators were selected as the final QI set through the process of appropriateness. The median appropriateness of these 12 indicators was at least 7.5, and all of them were without disagreement. The QI included assessment of disease activity, treatment of SLE, drug toxicity monitoring, treatment of glucocorticoid complications, and assessment of SLE complications. Conclusion: We formulated 12 QIs for the assessment of patients with SLE based on electronic medical data. Our QI set would be a practical tool as a quality measure.
KW - Performance measures
KW - quality indicators
KW - quality measures
KW - systemic lupus erythematosus
UR - http://www.scopus.com/inward/record.url?scp=85068132815&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85068132815&partnerID=8YFLogxK
U2 - 10.1080/14397595.2019.1621419
DO - 10.1080/14397595.2019.1621419
M3 - Article
C2 - 31111758
AN - SCOPUS:85068132815
SN - 1439-7595
VL - 30
SP - 525
EP - 531
JO - Japanese Journal of Rheumatology
JF - Japanese Journal of Rheumatology
IS - 3
ER -